{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:59:27Z","timestamp":1790675967926,"version":"4.1.0"},"reference-count":52,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Isavuconazole (ISA) is a triazole drug approved for the treatment of invasive aspergillosis and mucormycosis. Due to the relatively low interindividual variability of ISA pharmacokinetics and the lack of defined cutoffs for efficacy and toxicity, therapeutic drug monitoring (TDM) is rarely performed. This study aimed to characterize ISA pharmacokinetics and pharmacodynamics in real-life clinical settings and assess the potential role of TDM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We developed and validated a classical population pharmacokinetic (popPK) model using ISA concentrations obtained from patients undergoing TDM at three Swiss university hospitals. Additionally, we performed exploratory pharmacokinetic-pharmacodynamic analyses to investigate associations between ISA trough concentration or AUC, treatment outcomes, and hepatotoxicity using logistic regression models. Model-based simulations allowed assessing the role of TDM in clinical patient management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A one-compartment model with interindividual variability in clearance best described our data. Among the covariates tested, only body mass index was found to influence the ISA volume of distribution to a clinically significant extent. Exposure-response analyses suggested a trend toward an association with treatment success, but not with toxicity. Model-based simulations show that TDM could increase the proportion of patients within the currently suggested ISA target ranges.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our results indicate that ISA exposure shows substantial variability and tends to correlate with outcome. This suggests a beneficial role for TDM in optimizing target achievement.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jacamr\/dlag071","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T11:39:35Z","timestamp":1776339575000},"source":"Crossref","is-referenced-by-count":0,"title":["Characterization of isavuconazole pharmacokinetics and pharmacodynamics in a real-life cohort"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6419-9317","authenticated-orcid":false,"given":"Monia","family":"Guidi","sequence":"first","affiliation":[{"name":"Service of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne , Lausanne ,","place":["Switzerland"]},{"name":"Centre for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and University of Lausanne , Lausanne ,","place":["Switzerland"]},{"name":"Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva , Geneva ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jade","family":"Couchepin","sequence":"additional","affiliation":[{"name":"Infectious Diseases Service, Department of Medicine, Lausanne University Hospital and University of Lausanne , Lausanne ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilana","family":"Reinhold","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hospital Epidemiology, University Hospital of Zurich and University of Zurich , Zurich ,","place":["Switzerland"]},{"name":"University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Excellence Center for Medical Mycology , Cologne ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilona","family":"Kronig","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University Hospital of Geneva , Geneva ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dionysios","family":"Neofytos","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University Hospital of Geneva , Geneva ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Werner","family":"Schreiber","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hospital Epidemiology, University Hospital of Zurich and University of Zurich , Zurich ,","place":["Switzerland"]},{"name":"Department of Infectious Diseases and Infection Prevention, Lucerne Cantonal Hospital , Lucerne ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Andr\u00e9","sequence":"additional","affiliation":[{"name":"Service of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne , Lausanne ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Buclin","sequence":"additional","affiliation":[{"name":"Service of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne , Lausanne ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1023-5597","authenticated-orcid":false,"given":"Frederic","family":"Lamoth","sequence":"additional","affiliation":[{"name":"Infectious Diseases Service, Department of Medicine, Lausanne University Hospital and University of Lausanne , Lausanne ,","place":["Switzerland"]},{"name":"Institute of Microbiology, Lausanne University Hospital and University of Lausanne , Lausanne ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,5]]},"reference":[{"key":"2026092905165317800_dlag071-B1","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1086\/651263","article-title":"Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database","volume":"50","author":"Kontoyiannis","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2026092905165317800_dlag071-B2","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1086\/651262","article-title":"Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET)","volume":"50","author":"Pappas","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2026092905165317800_dlag071-B3","first-page":"1068","article-title":"The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study","volume":"91","author":"Pagano","year":"2006","journal-title":"Haematologica"},{"key":"2026092905165317800_dlag071-B4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1586\/14787210.2015.990382","article-title":"Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases","volume":"13","author":"Seyedmousavi","year":"2015","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"Suppl 1","key":"2026092905165317800_dlag071-B5","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2026092905165317800_dlag071-B6","doi-asserted-by":"publisher","first-page":"e405","DOI":"10.1016\/S1473-3099(19)30312-3","article-title":"Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium","volume":"19","author":"Cornely","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2026092905165317800_dlag071-B7","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"2026092905165317800_dlag071-B8","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1007\/s40262-018-0673-2","article-title":"Clinical pharmacokinetics and pharmacodynamics of isavuconazole","volume":"57","author":"McCarthy","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"2026092905165317800_dlag071-B9","doi-asserted-by":"publisher","first-page":"5483","DOI":"10.1128\/AAC.02819-15","article-title":"Population pharmacokinetics of isavuconazole from phase 1 and phase 3 (SECURE) trials in adults and target attainment in patients with invasive infections due to Aspergillus and other filamentous fungi","volume":"60","author":"Desai","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2026092905165317800_dlag071-B10","doi-asserted-by":"publisher","first-page":"4568","DOI":"10.1128\/AAC.00514-16","article-title":"Isavuconazole population pharmacokinetic analysis using nonparametric estimation in patients with invasive fungal disease (results from the VITAL study)","volume":"60","author":"Kovanda","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2026092905165317800_dlag071-B11","doi-asserted-by":"publisher","DOI":"10.1093\/mmy\/myae083","article-title":"A global perspective of the changing epidemiology of invasive fungal disease and real-world experience with the use of isavuconazole","volume":"62","author":"Thompson","year":"2024","journal-title":"Med Mycol"},{"key":"2026092905165317800_dlag071-B12","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01034-17","article-title":"Exposure-response relationships for isavuconazole in patients with invasive aspergillosis and other filamentous fungi","volume":"61","author":"Desai","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2026092905165317800_dlag071-B13","doi-asserted-by":"publisher","first-page":"5642","DOI":"10.1128\/AAC.01354-13","article-title":"Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model","volume":"57","author":"Lepak","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2026092905165317800_dlag071-B14","doi-asserted-by":"crossref","first-page":"6284","DOI":"10.1128\/AAC.01355-13","article-title":"Isavuconazole (BAL4815) pharmacodynamic target determination in an in vivo murine model of invasive pulmonary aspergillosis against wild-type and cyp51 mutant isolates of Aspergillus fumigatus","volume":"57","author":"Lepak","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2026092905165317800_dlag071-B15","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1128\/AAC.04907-14","article-title":"Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model","volume":"59","author":"Seyedmousavi","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2026092905165317800_dlag071-B16","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1093\/jac\/dkw098","article-title":"Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints","volume":"71","author":"Kovanda","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2026092905165317800_dlag071-B17","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00290-21","article-title":"Safety, tolerability, and population pharmacokinetics of intravenous and oral isavuconazonium sulfate in pediatric patients","volume":"65","author":"Arrieta","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2026092905165317800_dlag071-B18","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1002\/cpt.620","article-title":"QT interval shortening with isavuconazole: in vitro and in vivo effects on cardiac repolarization","volume":"101","author":"Keirns","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"2026092905165317800_dlag071-B19","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1093\/jac\/dky463","article-title":"Variability and exposure-response relationships of isavuconazole plasma concentrations in the phase 3 SECURE trial of patients with invasive mould diseases","volume":"74","author":"Kaindl","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2026092905165317800_dlag071-B20","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1086\/524669","article-title":"Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes","volume":"46","author":"Pascual","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2026092905165317800_dlag071-B21","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/clpt.2010.64","article-title":"Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma","volume":"88","author":"Jang","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"2026092905165317800_dlag071-B22","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00585-18","article-title":"Isavuconazole concentration in real-world practice: consistency with results from clinical trials","volume":"62","author":"Andes","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2026092905165317800_dlag071-B23","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1002\/phar.2850","article-title":"Utility of triazole antifungal therapeutic drug monitoring: insights from the Society of Infectious Diseases Pharmacists: endorsed by the Mycoses Study Group Education and Research Consortium","volume":"43","author":"McCreary","year":"2023","journal-title":"Pharmacotherapy"},{"key":"2026092905165317800_dlag071-B24","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis","volume":"16","author":"Marty","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2026092905165317800_dlag071-B25","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01643-18","article-title":"Pharmacokinetics of intravenous isavuconazole in solid-organ transplant recipients","volume":"62","author":"Wu","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2026092905165317800_dlag071-B26","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01728-19","article-title":"Population pharmacokinetics of intravenous isavuconazole in solid-organ transplant recipients","volume":"64","author":"Wu","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2026092905165317800_dlag071-B27","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.3390\/pharmaceutics13122099","article-title":"Population pharmacokinetics and pharmacodynamic target attainment of isavuconazole against Aspergillus fumigatus and Aspergillus flavus in adult patients with invasive fungal diseases: should therapeutic drug monitoring for isavuconazole be considered as mandatory as for the other mold-active azoles?","volume":"13","author":"Cojutti","year":"2021","journal-title":"Pharmaceutics"},{"key":"2026092905165317800_dlag071-B28","doi-asserted-by":"publisher","first-page":"5756","DOI":"10.3390\/jcm11195756","article-title":"Variability of isavuconazole trough concentrations during longitudinal therapeutic drug monitoring","volume":"11","author":"Bolcato","year":"2022","journal-title":"J Clin Med"},{"key":"2026092905165317800_dlag071-B29","doi-asserted-by":"publisher","first-page":"706","DOI":"10.3390\/antibiotics13080706","article-title":"Isavuconazole pharmacokinetics in critically ill patients: relationship with clinical effectiveness and patient safety","volume":"13","author":"Martin-Cerezuela","year":"2024","journal-title":"Antibiotics (Basel)"},{"key":"2026092905165317800_dlag071-B30","doi-asserted-by":"publisher","first-page":"946","DOI":"10.3390\/life15060946","article-title":"Optimization of isavuconazole dosing in patients with invasive fungal infections through therapeutic drug monitoring: real-world clinical practice experience","volume":"15","author":"Pena-Lorenzo","year":"2025","journal-title":"Life (Basel)"},{"key":"2026092905165317800_dlag071-B31","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1093\/jac\/dkz188","article-title":"Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy","volume":"74","author":"Furfaro","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2026092905165317800_dlag071-B32","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01511-20","article-title":"Isavuconazole therapeutic drug monitoring during long-term treatment for chronic pulmonary aspergillosis","volume":"65","author":"Kosmidis","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2026092905165317800_dlag071-B33","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1093\/jac\/dkaf128","article-title":"Isavuconazole therapeutic drug monitoring and association with adverse events","volume":"80","author":"Huang","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"2026092905165317800_dlag071-B34","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae223","article-title":"Isavuconazole for the treatment of fungal infections: a real-life experience from the Fungal Infection Network of Switzerland (FUNGINOS)","volume":"11","author":"Couchepin","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2026092905165317800_dlag071-B35","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026092905165317800_dlag071-B36","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1086\/590566","article-title":"Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria","volume":"47","author":"Segal","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2026092905165317800_dlag071-B37","author":"Astrand"},{"key":"2026092905165317800_dlag071-B38","doi-asserted-by":"publisher","first-page":"207","DOI":"10.32614\/RJ-2017-009","article-title":"imputeTS: time series missing value imputation in R","volume":"9","author":"Moritz","year":"2017","journal-title":"R J"},{"key":"2026092905165317800_dlag071-B39","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.21105\/joss.01686","article-title":"Welcome to the tidyverse","volume":"4","author":"Wickham","year":"2019","journal-title":"J Open Source Softw"},{"key":"2026092905165317800_dlag071-B40","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-24277-4","volume-title":"ggplot2: Elegant Graphics for Data Analysis","author":"Wickham","year":"2016"},{"key":"2026092905165317800_dlag071-B41","author":"R Core Team"},{"key":"2026092905165317800_dlag071-B42","author":"Robinson"},{"key":"2026092905165317800_dlag071-B43","author":"Pfizer Inc"},{"key":"2026092905165317800_dlag071-B44","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in Renal Disease Study Group","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"2026092905165317800_dlag071-B45","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","article-title":"Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models","volume":"13","author":"Bergstrand","year":"2011","journal-title":"AAPS J"},{"key":"2026092905165317800_dlag071-B46","doi-asserted-by":"publisher","first-page":"7559","DOI":"10.2147\/IDR.S434622","article-title":"Population pharmacokinetics of isavuconazole in adult: a systematic review","volume":"16","author":"Chen","year":"2023","journal-title":"Infect Drug Resist"},{"key":"2026092905165317800_dlag071-B47","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1093\/mmy\/myaa022","article-title":"Lessons from isavuconazole therapeutic drug monitoring at a United Kingdom reference center","volume":"58","author":"Borman","year":"2020","journal-title":"Med Mycol"},{"key":"2026092905165317800_dlag071-B48","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40261-025-01432-z","article-title":"An overview of isavuconazole clinical use: a multicentre analysis of indications, exposure and hepatic safety","volume":"45","author":"Bienvenu","year":"2025","journal-title":"Clin Drug Investig"},{"key":"2026092905165317800_dlag071-B49","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1093\/jac\/dkae139","article-title":"Isavuconazole as prophylaxis and therapy for invasive fungal diseases: a real-life observational study","volume":"79","author":"Ergun","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2026092905165317800_dlag071-B50","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1007\/s40262-023-01305-8","article-title":"Population pharmacokinetics of total and unbound isavuconazole in critically ill patients: implications for adaptive dosing strategies","volume":"62","author":"Jansen","year":"2023","journal-title":"Clin Pharmacokinet"},{"key":"2026092905165317800_dlag071-B51","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1080\/14740338.2017.1270264","article-title":"Clinical hepatotoxicity associated with antifungal agents","volume":"16","author":"Kyriakidis","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"2026092905165317800_dlag071-B52","doi-asserted-by":"publisher","first-page":"324","DOI":"10.3390\/jof6040324","article-title":"Isavuconazole: mechanism of action, clinical efficacy, and resistance","volume":"6","author":"Ellsworth","year":"2020","journal-title":"J Fungi (Basel)"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/8\/3\/dlag071\/68209609\/dlag071.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/8\/3\/dlag071\/68209609\/dlag071.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:17:00Z","timestamp":1790673420000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/doi\/10.1093\/jacamr\/dlag071\/8667181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,4,30]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlag071","relation":{},"ISSN":["2632-1823"],"issn-type":[{"value":"2632-1823","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,4,30]]},"article-number":"dlag071"}}